Connect with us

Artificial Intelligence

Electronic Health Record Market to achieve over 5.5% CAGR up to 2025: Global Market Insights, Inc.

Vlad Poptamas

Published

on

 

Global Electronic Health Record Market is expected to cross USD 38 billion by 2025; according to a new research report by Global Market Insights, Inc. Increasing government expenditure and funding for the development of healthcare IT solution for better understanding of diagnosis and treatment pattern will contribute to considerable EHR market growth over projected timeframe. Additionally, rising internet penetration and campaigns conducted to increase awareness about the importance and benefit of EHR among the doctor community will significantly expand the business size. Thus, growing awareness of EHR in hospitals and healthcare settings will accelerate the demand for electronic medical record systems over forthcoming years.

Increasing implementation of electronic health records will foster the global electronic health records industry growth in the upcoming period. Electronic healthcare records are used for systematic collection of patient’s health records in a digital format for better understanding of diagnosis and clinical treatment procedure. Rising adoption of electronic healthcare record for streamlining workflow and enhancing patient care delivery will positively impact adoption of electronic medical records in the forthcoming years.

Request for a sample of this research report @ https://www.gminsights.com/request-sample/detail/3130

However, dearth of capable professionals to handle advanced technology and high cost of EHR systems may hamper the market growth over the upcoming years.

On-premise EHR software market held more than 48% revenue share in 2018. Simultaneous access to multiple users, automation of elimination of redundant processes coupled with better safety of patient information are the major factors attributable to the segmental growth. Rising advancements in EHR technology such as increased work efficiency in controlled medical vocabulary and clinical decision support system should drive the consumer preference for on-premise EHR.

E-prescription application market is estimated to witness considerable growth over forecast period at 6.3% CAGR. E-prescription offers alternatives to the pharmacists to choose among various generic drugs as well as potentially allergic reactions. This feature enables safe and reliable documentation with less errors owing to illegible writing style of the prescribers. Additionally, flexibility of management of broad range of data points in drug store management will offer attractive growth opportunity for e-prescription market growth in the future years.

Electronic Health Record Market, By Application

1.1. Key segment trends

1.2. E-prescription

1.2.1. Market size, by region, 2014-2025 (USD Million)

1.3. Practice management

1.3.1. Market size, by region, 2014-2025 (USD Million)

1.4. Referral management

1.4.1. Market size, by region, 2014-2025 (USD Million)

1.5. Patient management

1.5.1. Market size, by region, 2014-2025 (USD Million)

1.6. Population health management

1.6.1. Market size, by region, 2014-2025 (USD Million)

1.7. Others

1.7.1. Market size, by region, 2014-2025 (USD Million)

Browse key industry insights spread across 157 pages with 174 market data tables & 12 figures & charts from the report, “Electronic Health Record Market Size By Product (Web/Cloud Based EHR Software, On-premise EHR Software), By Application (E-prescription, Practice Management, Referral Management, Patient Management, Population Health Management), By End-use (Hospitals, Specialty Centers, Clinics, Ambulatory Surgical Centers), Industry Analysis Report, Country Outlook (U.S., CanadaGermany, UK, FranceSpainItalyRussiaJapanChinaIndiaAustraliaBrazilMexicoSouth AfricaSaudi Arabia), Application Potential, Price Trends, Competitive Market Share & Forecast, 2019 – 2025” in detail along with the table of contents:

https://www.gminsights.com/industry-analysis/electronic-health-record-market

Specialty centers segment of electronic health record market accounted for USD 3.5 billion market size in 2018. Escalating demand for diagnostics owing to rising prevalence of genetic and orphan disease forms the major impact factor in adoption of electronic solutions. Presence of special software for specialty centers further drives its adoption rate among specialty centers over the forthcoming years. Furthermore, developing healthcare infrastructure in emerging economies should augment the segmental growth in the forecast years.

Canadian electronic health record market will witness rapid growth at 4.3% CAGR in upcoming years. Rising implementation of EHR in the Canada across all physicians and healthcare providers will pose to be high market growth impacting factor. Rising number of pharmacovigilance research organizations and hospitals will increase the demand for EHR system software. Furthermore, presence of established market players in the nation will highly impact Canadian electronic health record industry size in upcoming years.

Indian EHR market held over 18.0% market share in 2018 and will witness progressive growth over forecasted period. Wide accessibility of EHR in specialty centers and hospital attached research centers will spur the market growth over upcoming years. Several providers of electronic health record systems in India are focusing on innovation of EHR. Furthermore, growing awareness pertaining to the benefits of electronic health record will expand India electronic health record market growth over coming years.

Few notable players operating in electronic health record market are Allscripts, Cerner, eClinicalWorks, GE Healthcare and Epic Systems among the other industry players. Companies are implementing new product launch and product improvement strategy for capturing higher market share.

Make an inquiry for purchasing this report @ https://www.gminsights.com/inquiry-before-buying/3130

Browse Related Reports:

Digital Health Market Statistics 2019-2025: Telehealthcare business is expected to grow at 29.4% CAGR up to 2025. Rising geriatric population base, increasing demand for home-based remote monitoring systems are the some of the key drivers of global telehealth market growth. Key industry participants in global market include McKesson Corporation, Allscripts Healthcare Solutions Inc., Cisco Systems, Inc., Qualcomm, Philips Healthcare, eClinicalWorks LLC.

 

SOURCE Global Market Insights, Inc.

Artificial Intelligence

Deep Learning Market Size Worth US$ 56,427.2 Mn By 2026

GlobeNewswire

Published

on

LOS ANGELES, Jan. 27, 2020 (GLOBE NEWSWIRE) — The global deep learning market is expected to grow at a CAGR of around 51.1% over the forecast period 2019 to 2026 and reach the market value of over US$ 56,427.2 million by 2026.

North America held the major share of the global deep learning market in 2018. The well-established technology infrastructure of the region is supporting market growth. The high demand for deep learning application in healthcare, aerospace & defense, automotive, and telecommunications sector is contributing to the market growth.

Free Download Sample Report Pages for Better Understanding@ https://www.acumenresearchandconsulting.com/request-sample/1697

Hardware components accounted for the major share in 2018 and the t is also anticipated to maintain its dominance during the forecast timeframe 2019 to 2026. The hardware is required to increase the efficiency of deep learning applications is particularly supporting segment growth.

On the basis of application, the image recognition segment held the dominating share in the deep learning market. The increasing demand for optical character recognition and for identifying and detecting an object or a feature in a digital image or video is particularly accelerating the market value.

Security segment accounted for the major share by end-user in 2018. The segment is particularly gaining growth due to rising number of cyber attacks in various industry verticals. The increasing dependency of organizations on the data create need to figure out patterns from the available data for efficient decision making process. For instance, Oracle is developing Financial Crime and Compliance Studio (FCC Studio) with the help of deep learning and graph analytics. The new development is intended to detect repetitive patterns in graphs of data of individuals particularly to assist know-your-customer (KYC) and anti-money laundering (AML) activities.

View Detail Information with Complete TOC@ https://www.acumenresearchandconsulting.com/deep-learning-market

Some of the leading competitors are Amazon Web Services (AWS), Google, IBM, Intel, Micron Technology, Microsoft, Nvidia, Qualcomm, Samsung Electronics, Sensory Inc., Skymind, Xilinx, AMD, General Vision, Graphcore, Mellanox Technologies, Huawei Technologies, Fujitsu, Baidu, Mythic, Adapteva, Inc., and Koniku. Deep learning companies have announced mergers and acquisitions to expand their position in the deep learning industry. Major players are also moving into new regions or advanced technologies. For instance, Intel has acquired artificial intelligence chipmaker Habana Labs in 2019 for approx. US$ 2 billion to gain a competitive advantage and also to enhance its deep learning AI capability by increasing its portfolio.

Some of the key observations regarding deep learning industry include:

  • Amazon has officially launched an open-source toolkit on 9th January 2020. The toolkit name AutoGluon is designed for automated machine learning for providing ease to software developers in taking advantage of deep learning models. The new kit is designed for both machine learning experts and beginners to achieve strong, predictive performance in their application.
  • Salk Institute researchers have developed a new microscopy approach for faster brain imaging by 16 times. The researchers have used data from the Texas Advanced Computing Center (TACC), the University of Texas to train their deep learning system.
  • KaiKuTek, a Taiwan based startup led by Taiwan Tech Arena (TTA) has showcased innovative solutions in January at Consumer Electronics Show (CES) 2020. KaiKuTek has developed world-first 60GHz gesture recognition SoC that combines deep learning algorithms, and AI accelerators named mmWave.
  • QuEST Global has demonstrated Deep Learning driven Advanced Driver Assistance Systems (ADAS) at CES 2020. The new deep learning model is intended to enhance ADAS by improving the accuracy in the detection of traffic signs, pedestrians and traffic.
  • Amazon has released Deep Java Library (DJL) at reinvent 2019. The new development is an open-source library with Java APIs particularly to simplify training, testing, deploying, and making predictions with the help of deep-learning models.
  • MATLAB software enables the simple and agile development of advance deep learning networks with higher speed, less memory and better results in 2020 with its new version.
  • Intel has shipped the industry’s first silicon for neural network processor in 2017 named Intel Nervana Neural Network Processor (NNP). The new processor is intended to develop entirely new classes of artificial intelligence applications to maximize the amount of data processed and enable customers to find greater insights with deep learning models.

Request for Customization@ https://www.acumenresearchandconsulting.com/request-customization/1697

The report is readily available and can be dispatched immediately after payment confirmation.

Buy this premium research report@ https://www.acumenresearchandconsulting.com/buy-now/0/1697

If you would like to place an order or have any questions, please feel free to contact at sales@acumenresearchandconsulting.com | +1 407 915 4157 OR +1 408 900 9135

For Latest Update Follow Us:

https://twitter.com/AcumenRC

https://www.facebook.com/acumenresearchandconsulting

https://www.linkedin.com/company/acumen-research-and-consulting/

Continue Reading

Artificial Intelligence

iCAD Showcases Technology for Cancer “Discovery to Recovery” including ProFound AI Platform and Xoft System at Arab Health 2020 in Dubai

GlobeNewswire

Published

on

NASHUA, N.H., Jan. 27, 2020 (GLOBE NEWSWIRE) — iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it will showcase its latest advancements in cancer detection and therapy, including ProFound AI™ and the Xoft® Axxent® Electronic Brachytherapy (eBx®) System®, in the iCAD exhibition booth (# S1.C71) at Arab Health 2020 in Dubai from January 27-30. Arab Health is the largest gathering of healthcare companies, technologies, products and services in the Middle East and North African (MENA) region.

“This medical meeting represents a significant milestone for the Company, as it is the first time iCAD’s technologies for both the detection and treatment of cancer will be exhibited together in the Middle East, where breast cancer rates are expected to double between 2012 and 2030 – the highest relative increase of any region globally,”1 according to Michael Klein, Chairman and CEO of iCAD. “A growing body of evidence suggests early cancer diagnosis leads to better outcomes,2,3,4 and demand continues to grow for increasingly targeted, more personalized treatment options. iCAD’s technology is congruent with both of these trending forces in healthcare today.”

iCAD’s Breast Health Solutions suite includes ProFound AI for Digital Breast Tomosynthesis (DBT), as well as software solutions for 2D mammography and breast density. ProFound AI is a high-performing workflow solution featuring the latest in deep-learning artificial intelligence capabilities. In December 2018, ProFound AI for DBT became the first artificial intelligence software for DBT to be cleared by the U.S. Food and Drug Administration; it was also CE marked and Health Canada licensed that same year. ProFound AI for 2D Mammography was CE marked in July 2019.

Intended to be used by radiologists reviewing mammography or DBT images, ProFound AI rapidly and accurately analyzes each individual image, or slice, and identifies potentially malignant lesions. Trained with one of the largest available image datasets, it provides radiologists with crucial information, such as Certainty of Finding lesion and Case Scores, which assists in clinical decision-making and prioritizing caseloads. The technology also allows for continuously improved performance via ongoing product updates.

Positive clinical data from a large reader study involving ProFound AI for DBT were recently published in Radiology: Artificial Intelligence.5 According to study findings, ProFound AI for DBT improved radiologist sensitivity by 8 percent, reduced unnecessary patient recall rates by 7.2 percent, and slashed reading time for radiologists by 52.7 percent.5 Additionally, ProFound AI for DBT cut reading time by up to 57.4 percent for radiologists reading cases with dense breasts.6

“ProFound AI increases my confidence reading 3D mammograms,” according to Lisa Sheppard, MD, PINK Breast Center. “We find this technology not only benefits our patients, reducing unnecessary callbacks and giving us more confidence when we recommend biopsies, ProFound AI fits with our workflow and protocols. Ultimately, this helps us continue to improve patient care.”

iCAD’s flagship product for cancer therapy is the Xoft System, which is FDA-cleared, CE marked and licensed in a growing number of countries for the treatment of cancer anywhere in the body, including early-stage breast cancer, non-melanoma skin cancers (NMSC), and gynecological cancers.

“The Xoft System is an innovative radiation oncology treatment solution that offers significant cost, mobility, and treatment time advantages over competitors or the standard of care,” according to Stacey Stevens, President of iCAD. “It offers a clinically-proven, single-fraction therapy for early-stage breast cancer, while also offering added flexibility to treat other types of cancers, including nonmelanoma skin cancers and gynecological cancers.”

The Xoft System uses a miniaturized x-ray source to deliver a precise, concentrated dose of radiation directly to the tumor site, while minimizing risk of damage to healthy tissue in nearby areas of the body. For the treatment of early-stage breast cancer, intraoperative radiation therapy (IORT) with the Xoft System allows appropriately selected patients to potentially replace four to six weeks of post-operative external beam radiation therapy (EBRT) with a single-fraction of radiation that can last as little as eight minutes.

The Company recently unveiled new and updated x-ray sources and the full suite of applicators for existing and emerging applications at the American Society for Radiation Oncology (ASTRO) Annual Meeting last year. These included applicators in development for minimally-invasive robotic surgery, such as prostate, an advanced prototype for early-stage rectal cancers, and extended-length balloon applicators, now available in 25 cm and 50 cm lengths, which offer added versatility and the potential for additional applications for Xoft eBx in different areas of the body. The Company also showcased its latest extended-life x-ray sources, which feature a ten-fold increase in treatment times, offering time-saving benefits for clinicians and enhancing efficiency. Additionally, the Company offers world-class treatment planning programs, developed for both the Xoft controller and general IORT with the Xoft System.

The full suite of currently available eBx applicators, including those with established data for early-stage breast cancer, gynecological cancers, nonmelanoma skin cancers, and most recently, brain cancers, will be available for demonstration in the iCAD booth throughout Arab Health 2020.

“ProFound AI and the Xoft System are currently available in a growing number of countries worldwide, and demand continues to grow as more clinicians and patients learn about the benefits our cancer detection and therapy solutions offer,” added Klein. “These leading-edge solutions empower physicians to offer more personalized care for patients and are paving the way towards a ‘discovery to recovery’ disease management plan and pathway that may improve patient outcomes in the years ahead as the cancer diagnosis and treatment paradigm continues to evolve.”

References:

1.)    Ginsburg O, Bray F, Coleman MP, Vanderpuye V, Eniu A, Kotha SR, et al. The global burden of women’s cancers: a grand challenge in global health. Lancet. (2017) 389:847–60. doi: 10.1016/S0140-6736(16)31392-7
2.)    Tabár, L. et al. Swedish two-county trial: impact of mammographic screening on breast cancer mortality during 3 decades. Radiology 260, 658–663 (2011).
3.)    The Canadian Task Force on Preventive Health Care. Recommendations on screening for breast cancer in average-risk women aged 40–74 years. CMAJ 183, 1991–2001 (2011).
4.)    Marmot, M. G. et al. The benefits and harms of breast cancer screening: an independent review. Br. J. Cancer 108, 2205–2240 (2013).
5.)    Conant, E. et al. (2019). Improving Accuracy and Efficiency with Concurrent Use of Artificial Intelligence for Digital Breast Tomosynthesis. Radiology: Artificial Intelligence. 1 (4). Accessed via https://pubs.rsna.org/doi/10.1148/ryai.2019180096
6.)    Hoffmeister, J. (2018). Artificial Intelligence for Digital Breast Tomosynthesis – Reader Study Results. [White paper]. Accessed via https://www.icadmed.com/assets/dmm253-reader-studies-results-rev-a.pdf

About iCAD, Inc.

Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions. For more information, visit www.icadmed.com.

Forward-Looking Statements

Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the future prospects for the Company’s technology platforms and products. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Company’s ability to defend itself in litigation matters, to achieve business and strategic objectives, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, uncertainty of future sales levels, protection of patents and other proprietary rights, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence of products, increased competition, litigation and/or government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe,” “demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,” “anticipate,” “likely,” “seek,” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.

Contacts:
Media inquiries:
Jessica Burns, iCAD  
+1-201-423-4492 Europe:
Emmanuelle Vella, iCAD
+33 6 20 49 48 57 Investor Relations:
Jeremy Feffer, LifeSci Advisors, on behalf of iCAD, Inc.
+1-212-915-2568

Continue Reading

Artificial Intelligence

Visteon to Announce Fourth-Quarter and Full-Year 2019 Results, Financial Outlook on Thursday, Feb. 20

GlobeNewswire

Published

on

VAN BUREN TOWNSHIP, Mich., Jan. 27, 2020 (GLOBE NEWSWIRE) — Visteon Corporation (Nasdaq: VC) plans to release its fourth-quarter and full-year 2019 financial results, and financial outlook, prior to 7 a.m. ET on Thursday, Feb. 20. The company will host a conference call for the investment community at 9 a.m. ET to discuss the results, outlook and related matters. The conference call also is available to the general public via a live audio webcast.

The dial-in numbers to participate in the call are:

U.S./Canada: 866-411-5196 
Outside U.S./Canada: 970-297-2404

(Call approximately 10 minutes before the start of the conference.)

The conference call and live audio webcast, related presentation materials, news release and other supplemental information will be accessible in the Investors section of Visteon’s website.

A replay of the conference call will be available through the company’s website or by dialing 855-859-2056 (toll-free from the U.S. and Canada) or 404-537-3406 (international). The conference ID for the phone replay is 5473059. The phone replay will be available for one week following the conference call.

About Visteon

Visteon is a global technology company that designs, engineers and manufactures innovative cockpit electronics and connected car solutions for the world’s major vehicle manufacturers. Visteon is driving the smart, learning, digital cockpit of the future, to improve safety and the user experience. Visteon is a global leader in cockpit electronic products including digital instrument clusters, information displays, infotainment, head-up displays, telematics, SmartCore™ cockpit domain controllers, and the DriveCore™ autonomous driving platform. Visteon also delivers artificial intelligence-based technologies, connected car, cybersecurity, interior sensing, embedded multimedia and smartphone connectivity software solutions. Headquartered in Van Buren Township, Michigan, Visteon has approximately 10,000 employees at more than 40 facilities in 18 countries. Visteon had sales of approximately $3 billion in 2018. Learn more at www.visteon.com.

Follow Visteon:

https://www.linkedin.com/company/visteon/?trk=vsrp_companies_res_photo&trkInfo=VSRPsearchId:522343161373310041683,VSRPtargetId:2865,VSRPcmpt:primary
https://twitter.com/visteon
https://www.facebook.com/VisteonCorporation
https://www.youtube.com/user/Visteon
http://www.slideshare.net/VisteonCorporation

https://www.instagram.com/visteon/
https://mp.weixin.qq.com/?lang=en_US
https://m.weibo.cn/u/6605315328
http://i.youku.com/u/UNDgyMjA1NjUxNg==?spm=a2h0k.8191407.0.0

Media:Contacts:

Amna Kamal
734-710-2566
akamal@visteon.com

Investors:

Kris Doyle
734-710-7893
kdoyle@visteon.com

Continue Reading

Trending

Roboticulized is part of PICANTE Media and Events, a leading media and boutique event organizer in the European Union with a monthly reach of +50,000 readers. The official company (PROSHIRT SRL), has been listed for 4 years in a row among the top 3 Advertising and market research agencies in the local Top Business Romania Microcompanies based on the Financial Reports. Roboticulized digests / hand picks the latest news about the AI industry and serves them to you daily.

Contact us: sales@picante.today

Editorial / PR Submissions

© Roboticulized.com 2019 - 2020 - part of PICANTE Media. All rights reserved. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania